QSC Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
The mechanism of action involves mimicking natural GIP at the GIP receptor while simultaneously activating GLP-1 receptors. QSC Tirzepatide shows particular promise in research applications due to its balanced receptor affinity profile and enhanced metabolic effects.
Our QSC Tirzepatide is supplied as a high-purity white powder with rigorous quality control standards. Each batch undergoes comprehensive analytical testing to ensure consistency and purity for research applications.
For laboratory use only. Not intended for human consumption. Researchers should handle all materials according to appropriate safety protocols and institutional guidelines.